Stock Scorecard
Stock Summary for Omeros Corporation (OMER) - $10.13 as of 10/16/2025 6:21:17 PM EST
Total Score
5 out of 30
Safety Score
34 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for OMER
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for OMER
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for OMER
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for OMER
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for OMER (34 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for OMER
Financial Details for OMER
Company Overview |
|
|---|---|
| Ticker | OMER |
| Company Name | Omeros Corporation |
| Country | USA |
| Description | Omeros Corporation is a Seattle-based biopharmaceutical firm that specializes in the discovery, development, and commercialization of novel therapeutics aimed at serious conditions. The company boasts a diverse pipeline featuring both protein and small molecule therapies, targeting critical unmet medical needs in areas such as inflammation, complement-mediated diseases, and central nervous system (CNS) disorders. With a strategic focus on orphan indications, Omeros is well-equipped to drive growth and make significant advancements in patient care, positioning itself as a leader in innovative treatment solutions. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/5/2025 |
Stock Price History |
|
| Last Day Price | 10.13 |
| Price 4 Years Ago | 6.43 |
| Last Day Price Updated | 10/16/2025 6:21:17 PM EST |
| Last Day Volume | 124,049,078 |
| Average Daily Volume | 5,354,667 |
| 52-Week High | 13.60 |
| 52-Week Low | 2.95 |
| Last Price to 52 Week Low | 243.39% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.57 |
| Sector PE | 40.88 |
| 5-Year Average PE | -2.03 |
| Free Cash Flow Ratio | 337.67 |
| Industry Free Cash Flow Ratio | 14.92 |
| Sector Free Cash Flow Ratio | 29.58 |
| Current Ratio Most Recent Quarter | 0.81 |
| Total Cash Per Share | 0.03 |
| Book Value Per Share Most Recent Quarter | -3.81 |
| Price to Book Ratio | 8.44 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.01 |
| Price to Sales Ratio Twelve Trailing Months | 4.93 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.74 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.92 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 68,056,000 |
| Market Capitalization | 689,407,280 |
| Institutional Ownership | 42.69% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 5.65% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -33.11% |
| Reported EPS 12 Trailing Months | -2.36 |
| Reported EPS Past Year | -0.97 |
| Reported EPS Prior Year | -2.79 |
| Net Income Twelve Trailing Months | -122,474,000 |
| Net Income Past Year | -156,815,000 |
| Net Income Prior Year | -117,813,000 |
| Quarterly Revenue Growth YOY | 14.90% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,904,000 |
| Total Cash Past Year | 3,400,000 |
| Total Cash Prior Year | 7,105,000 |
| Net Cash Position Most Recent Quarter | -148,883,000 |
| Net Cash Position Past Year | -163,183,000 |
| Long Term Debt Past Year | 166,583,000 |
| Long Term Debt Prior Year | 213,155,000 |
| Total Debt Most Recent Quarter | 150,787,000 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | -182,609,000 |
| Total Stockholder Equity Prior Year | -24,983,000 |
| Total Stockholder Equity Most Recent Quarter | -228,685,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -118,898,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.75 |
| Free Cash Flow Past Year | -148,968,000 |
| Free Cash Flow Prior Year | 74,300,000 |
Options |
|
| Put/Call Ratio | 1.17 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.08 |
| MACD Signal | 0.06 |
| 20-Day Bollinger Lower Band | 2.89 |
| 20-Day Bollinger Middle Band | 3.87 |
| 20-Day Bollinger Upper Band | 4.86 |
| Beta | 2.33 |
| RSI | 54.68 |
| 50-Day SMA | 6.38 |
| 150-Day SMA | 4.66 |
| 200-Day SMA | 4.67 |
System |
|
| Modified | 10/16/2025 6:01:39 AM EST |